{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:02:01Z","timestamp":1790402521728,"version":"4.1.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04278-2","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:49:13Z","timestamp":1790401753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune inflammatory targets and anti-inflammatory therapy in dry eye disease"],"prefix":"10.1007","volume":"46","author":[{"given":"Zongcan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibing","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"4278_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2025.05.040","volume":"279","author":"F Stapleton","year":"2025","unstructured":"Stapleton F, Arg\u00fceso P, Asbell P et al (2025) TFOS DEWS III: digest. Am J Ophthalmol 279:451\u2013553. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.040","journal-title":"Am J Ophthalmol"},{"key":"4278_CR2","unstructured":"Golden MI, Meyer JJ, Zeppieri M, Patel BC. Dry eye syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 29, 2024"},{"issue":"1","key":"4278_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/07853890.2022.2157477","volume":"55","author":"J Sheppard","year":"2023","unstructured":"Sheppard J, Shen Lee B, Periman LM (2023) Dry eye disease: identification and therapeutic strat-egies for primary care clinicians and clinical specialists. Ann Med 55(1):241\u2013252. https:\/\/doi.org\/10.1080\/07853890.2022.2157477","journal-title":"Ann Med"},{"issue":"23","key":"4278_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cells12232755","volume":"12","author":"CR Harrell","year":"2023","unstructured":"Harrell CR, Feulner L, Djonov V, Pavlovic D, Volarevic V (2023) The molecular mechanisms responsible for tear hyperosmolarity-induced pathological changes in the eyes of dry eye disease patients. Cells 12(23):2755. https:\/\/doi.org\/10.3390\/cells12232755","journal-title":"Cells"},{"key":"4278_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2023.1173683","volume":"5","author":"S Patel","year":"2023","unstructured":"Patel S, Mittal R, Kumar N, Galor A (2023) The environment and dry eye-manifestations, mechanisms, and more. Front Toxicol 5:1173683. https:\/\/doi.org\/10.3389\/ftox.2023.1173683","journal-title":"Front Toxicol"},{"issue":"10","key":"4278_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.jfo.2020.10.002","volume":"44","author":"\u00c9 Auffret","year":"2021","unstructured":"Auffret \u00c9, Gomart G, Bourcier T, Gaucher D, Speeg-Schatz C, Sauer A (2021) Perturbations oculaires secondaires \u00e0 l\u2019utilisation de supports num\u00e9riques. Sympt\u00f4mes pr\u00e9valence, physiopathologie et prise en charge Digital eye strain. Symptoms prevalence, pathophysiology. and management. J Fr Ophtalmol 44(10):1605\u20131610. https:\/\/doi.org\/10.1016\/j.jfo.2020.10.002","journal-title":"J Fr Ophtalmol"},{"issue":"10","key":"4278_CR7","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1007\/s10792-022-02320-7","volume":"42","author":"R Huang","year":"2022","unstructured":"Huang R, Su C, Fang L, Lu J, Chen J, Ding Y (2022) Dry eye syndrome: comprehensive etiologies and recent clinical trials. Int Ophthalmol 42(10):3253\u20133272. https:\/\/doi.org\/10.1007\/s10792-022-02320-7","journal-title":"Int Ophthalmol"},{"issue":"9","key":"4278_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60091458","volume":"60","author":"AC Britten-Jones","year":"2024","unstructured":"Britten-Jones AC, Wang MTM, Samuels I, Jennings C, Stapleton F, Craig JP (2024) Epidemiology and risk factors of dry eye disease: considerations for clinical management. Medicina (Kaunas) 60(9):1458. https:\/\/doi.org\/10.3390\/medicina60091458","journal-title":"Medicina (Kaunas)"},{"key":"4278_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.033","volume":"279","author":"JS Wolffsohn","year":"2025","unstructured":"Wolffsohn JS, Ben\u00edtez-Del-Castillo JM, Loya-Garcia D et al (2025) TFOS DEWS III: diagnostic methodology. Am J Ophthalmol 279:387\u2013450. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.033","journal-title":"Am J Ophthalmol"},{"key":"4278_CR10","doi-asserted-by":"publisher","first-page":"1307682","DOI":"10.3389\/fm-ed.2024.1307682","volume":"11","author":"L Chu","year":"2024","unstructured":"Chu L, Wang C, Zhou H (2024) Inflammation mechanism and anti-inflammatory therapy of dry eye. Front Med (Lausanne). 11:1307682. https:\/\/doi.org\/10.3389\/fm-ed.2024.1307682","journal-title":"Front Med (Lausanne)."},{"issue":"18","key":"4278_CR11","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1080\/14656566.2023.2269090","volume":"24","author":"G Coco","year":"2023","unstructured":"Coco G, Ambrosini G, Poletti S et al (2023) Recent advances in drug treatments for dry eye disease. Expert Opin Pharmacother 24(18):2059\u20132079. https:\/\/doi.org\/10.1080\/14656566.2023.2269090","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"4278_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40265-024-02031-6","volume":"84","author":"D Vald\u00e9s-Arias","year":"2024","unstructured":"Vald\u00e9s-Arias D, Locatelli EVT, Sepulveda-Beltran PA, Mangwani-Mordani S, Navia JC, Galor A (2024) Recent United States developments in the pharmacological treatment of dry eye disease. Drugs 84(5):549\u2013563. https:\/\/doi.org\/10.1007\/s40265-024-02031-6","journal-title":"Drugs"},{"key":"4278_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtos.2023.04.007","volume":"29","author":"M Alves","year":"2023","unstructured":"Alves M, Asbell P, Dogru M et al (2023) TFOS Lifestyle Report: impact of environmental con-ditions on the ocular surface. Ocul Surf 29:1\u201352. https:\/\/doi.org\/10.1016\/j.jtos.2023.04.007","journal-title":"Ocul Surf"},{"issue":"3","key":"4278_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.22336\/rjo.2023.42","volume":"67","author":"M Zemba","year":"2023","unstructured":"Zemba M, Ionescu MA, P\u00eervulescu RA et al (2023) Biomarkers of ocular allergy and dry eye d-isease. Rom J Ophthalmol 67(3):250\u2013259. https:\/\/doi.org\/10.22336\/rjo.2023.42","journal-title":"Rom J Ophthalmol"},{"key":"4278_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jtos.2026.06.003","volume":"41","author":"H Duan","year":"2026","unstructured":"Duan H, Sheng P, Zhang Y et al (2026) Dysregulated lipid metabolism in dry eye disease: path-ophysiological mechanisms and emerging treatments. Ocul Surf 41:185\u2013202. https:\/\/doi.org\/10.1016\/j.jtos.2026.06.003","journal-title":"Ocul Surf"},{"issue":"Pt 4","key":"4278_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.146182","volume":"320","author":"G Cho","year":"2025","unstructured":"Cho G, Lee D, Song S et al (2025) Molecular perspectives on protein-modulated tear film lipid layer stability in dry eye disease. Int J Biol Macromol 320(Pt 4):146182. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.146182","journal-title":"Int J Biol Macromol"},{"issue":"9","key":"4278_CR17","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/microorganis-ms13091992","volume":"13","author":"F Tariq","year":"2025","unstructured":"Tariq F, Hehar NK, Chigbu DI (2025) The ocular surface microbiome in homeostasis and dys-biosis. Microorganisms 13(9):1992. https:\/\/doi.org\/10.3390\/microorganis-ms13091992","journal-title":"Microorganisms"},{"key":"4278_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jtos.2024.12.010","volume":"36","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Liu C, Zhao L, Yao J (2025) Systems biology of dry eye: unraveling molecular mechanisms through multi-omics integration. Ocul Surf 36:25\u201340. https:\/\/doi.org\/10.1016\/j.jtos.2024.12.010","journal-title":"Ocul Surf"},{"issue":"Suppl 1","key":"4278_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0133-9","volume":"15","author":"KS Na","year":"2015","unstructured":"Na KS, Hwang KY, Lee HS, Chung SH, Mok JW, Joo CK (2015) Wakayama symposium: interface between innate and adaptive immunity in dry eye disease. BMC Ophthalmol 15(Suppl 1):159. https:\/\/doi.org\/10.1186\/s12886-015-0133-9","journal-title":"BMC Ophthalmol"},{"key":"4278_CR20","doi-asserted-by":"publisher","first-page":"815075","DOI":"10.3389\/fmed.2021.815075","volume":"8","author":"J Ling","year":"2022","unstructured":"Ling J, Chan BC, Tsang MS, Gao X, Leung PC, Lam CW, Hu JM, Wong CK (2022) Current advances in mechanisms and treatment of dry eye disease: toward anti-inflammatory and immunomodulatory therapy and traditional chinese medicine. Front Med (Lausanne) 8:815075. https:\/\/doi.org\/10.3389\/fmed.2021.815075","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"4278_CR21","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.4103\/IJO.IJO_481_23","volume":"71","author":"RP Kaur","year":"2023","unstructured":"Kaur RP, Gurnani B, Kaur K (2023) Intricate insights into immune response in dry eye disease. Indian J Ophthalmol 71(4):1248\u20131255. https:\/\/doi.org\/10.4103\/IJO.IJO_481_23","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"4278_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41433-024-03512-4","volume":"39","author":"JV Forrester","year":"2025","unstructured":"Forrester JV, McMenamin PG (2025) Evolution of the ocular immune system. Eye (Lond) 39(3):468\u2013477. https:\/\/doi.org\/10.1038\/s41433-024-03512-4","journal-title":"Eye (Lond)"},{"issue":"1","key":"4278_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05533-4","volume":"82","author":"Y Huang","year":"2025","unstructured":"Huang Y, Zhang G, Li S, Feng J, Zhang Z (2025) Innate and adaptive immunity in neurodegen-erative disease. Cell Mol Life Sci 82(1):68. https:\/\/doi.org\/10.1007\/s00018-024-05533-4","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"4278_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-immunol-083122-040624","volume":"43","author":"KA Warrick","year":"2025","unstructured":"Warrick KA, Vallez CN, Meibers HE, Pasare C (2025) Bidirectional communication between the innate and adaptive immune systems. Annu Rev Immunol 43(1):489\u2013514. https:\/\/doi.org\/10.1146\/annurev-immunol-083122-040624","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"4278_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02607-2","volume":"30","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Zhang L, Chen B (2025) Characterization of T cells in the progression of dry eye disease using single-cell RNA sequencing in mice. Eur J Med Res 30(1):338. https:\/\/doi.org\/10.1186\/s40001-025-02607-2","journal-title":"Eur J Med Res"},{"issue":"14","key":"4278_CR26","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1167\/iovs.17-22852","volume":"58","author":"X Zhang","year":"2017","unstructured":"Zhang X, Lin X, Liu Z et al (2017) Topical application of mizoribine suppresses CD4+ T-cell-mediated pathogenesis in murine dry eye. Invest Ophthalmol Vis Sci 58(14):6056\u20136064. https:\/\/doi.org\/10.1167\/iovs.17-22852","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4278_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2024.110006","volume":"246","author":"G Ortiz","year":"2024","unstructured":"Ortiz G, Blanco T, Singh RB et al (2024) IL-6 induces Treg dysfunction in desiccating stress-induced dry eye disease. Exp Eye Res 246:110006. https:\/\/doi.org\/10.1016\/j.exer.2024.110006","journal-title":"Exp Eye Res"},{"issue":"7","key":"4278_CR28","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.ajpath.2020.03.016","volume":"190","author":"W Foulsham","year":"2020","unstructured":"Foulsham W, Mittal SK, Taketani Y et al (2020) Aged mice exhibit severe exacerbations of dry eye disease with an amplified memory Th17 cell response. Am J Pathol 190(7):1474\u20131482. https:\/\/doi.org\/10.1016\/j.ajpath.2020.03.016","journal-title":"Am J Pathol"},{"key":"4278_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jaut.2017.02.006","volume":"80","author":"W Chi","year":"2017","unstructured":"Chi W, Hua X, Chen X et al (2017) Mitochondrial DNA oxidation induces imbalanced activity of NLRP3\/NLRP6 inflammasomes by activation of caspase-8 and BRCC36 in dry eye. J Autoimmun 80:65\u201376. https:\/\/doi.org\/10.1016\/j.jaut.2017.02.006","journal-title":"J Autoimmun"},{"issue":"2","key":"4278_CR30","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.2.10","volume":"66","author":"Y Li","year":"2025","unstructured":"Li Y, Luo Z, Liu Z et al (2025) IL-23 promotes \u03b3\u03b4T cell activity in dry eye disease progression. Invest Ophthalmol Vis Sci 66(2):10. https:\/\/doi.org\/10.1167\/iovs.66.2.10","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"17","key":"4278_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202415341","volume":"12","author":"L Zhao","year":"2025","unstructured":"Zhao L, Li X, Gao M et al (2025) M6A modified miR-31-5p suppresses M1 macrophage polarization and autoimmune dry eye by targeting P2RX7. Adv Sci 12(17):e2415341. https:\/\/doi.org\/10.1002\/advs.202415341","journal-title":"Adv Sci"},{"key":"4278_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8821610","author":"Y Peng","year":"2023","unstructured":"Peng Y, Zhou M, Yang H et al (2023) Regulatory mechanism of M1\/M2 macrophage polarization in the development of autoimmune diseases. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2023\/8821610","journal-title":"Mediators Inflamm"},{"key":"4278_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101553","volume":"74","author":"I Mart\u00ednez-Alberquilla","year":"2022","unstructured":"Mart\u00ednez-Alberquilla I, Gasull X, P\u00e9rez-Luna P, Seco-Mera R, Ruiz-Alcocer J, Crooke A (2022) Neutrophils and neutrophil extracellular trap components: Emerging biomarkers and therap-eutic targets for age-related eye diseases. Ageing Res Rev 74:101553. https:\/\/doi.org\/10.1016\/j.arr.2021.101553","journal-title":"Ageing Res Rev"},{"issue":"3","key":"4278_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/jop.2019.0060","volume":"36","author":"LM Periman","year":"2020","unstructured":"Periman LM, Perez VL, Saban DR, Lin MC, Neri P (2020) The immunological basis of dry eye disease and current topical treatment options. J Ocul Pharmacol Ther 36(3):137\u2013146. https:\/\/doi.org\/10.1089\/jop.2019.0060","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"4278_CR35","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/09273948.2020.1870148","volume":"30","author":"A Shahriary","year":"2022","unstructured":"Shahriary A, Sabzevari M, Jadidi K, Yazdani F, Aghamollaei H (2022) The role of inflammatory cytokines in neovascularization of chemical ocular injury. Ocul Immunol Inflamm 30(5):1149\u20131161. https:\/\/doi.org\/10.1080\/09273948.2020.1870148","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"4278_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15031269","volume":"15","author":"C Shields","year":"2026","unstructured":"Shields C, Davila N, Hattenhauer A, Qazi S, Galor A, Donthineni PR (2026) Emerging technologies in corneal nerve evaluation for dry eye and ocular surface disease: a review. J Clin Med 15(3):1269. https:\/\/doi.org\/10.3390\/jcm15031269","journal-title":"J Clin Med"},{"issue":"6","key":"4278_CR37","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.6.13","volume":"66","author":"M Qu","year":"2025","unstructured":"Qu M, Bai X, Zhang M et al (2025) Activation of sympathetic nervous system drives dry eye onset via norepinephrine-\u03b22-adrenergic receptor signaling in mice. Invest Ophthalmol Vis Sci 66(6):13. https:\/\/doi.org\/10.1167\/iovs.66.6.13","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"4278_CR38","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1038\/s41467-025-60476-z","volume":"16","author":"M Qu","year":"2025","unstructured":"Qu M, Wang Q, Bai X et al (2025) A gatekeeper sympathetic control of lacrimal tear secretion and dry eye onset through the NA-Adra1a-Ucp2 pathway. Nat Commun 16(1):5215. https:\/\/doi.org\/10.1038\/s41467-025-60476-z","journal-title":"Nat Commun"},{"key":"4278_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118625","volume":"192","author":"T Migeon","year":"2025","unstructured":"Migeon T, Cordovilla A, Potey A et al (2025) TRPA1 inhibition reduces ocular pain and corneal neurogenic inflammation in a mouse model of dry eye disease. Biomed Pharmacother 192:118625. https:\/\/doi.org\/10.1016\/j.biopha.2025.118625","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"4278_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/biom15050729","volume":"15","author":"I Jastrz\u0119bska-Miazga","year":"2025","unstructured":"Jastrz\u0119bska-Miazga I, Machna B, Wygl\u0119dowska-Promie\u0144ska D, Sm\u0119dowski A (2025) The role of substance P in corneal homeostasis. Biomolecules 15(5):729. https:\/\/doi.org\/10.3390\/biom15050729","journal-title":"Biomolecules"},{"key":"4278_CR41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jtos.2022.06.007","volume":"25","author":"RB Singh","year":"2022","unstructured":"Singh RB, Naderi A, Cho W et al (2022) Modulating the tachykinin: role of substance P and neurokinin receptor expression in ocular surface disorders. Ocul Surf 25:142\u2013153. https:\/\/doi.org\/10.1016\/j.jtos.2022.06.007","journal-title":"Ocul Surf"},{"issue":"11","key":"4278_CR42","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.11.58","volume":"66","author":"Z Lin","year":"2025","unstructured":"Lin Z, Verma B, Zhu S et al (2025) Calcitonin gene-related peptide ameliorates experimental dry eye disease. Invest Ophthalmol Vis Sci 66(11):58. https:\/\/doi.org\/10.1167\/iovs.66.11.58","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"15","key":"4278_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cells13151251","volume":"13","author":"C Song","year":"2024","unstructured":"Song C, Seong H, Yoo WS et al (2024) Diquafosol improves corneal wound healing by inducing NGF expression in an experimental dry eye model. Cells 13(15):1251. https:\/\/doi.org\/10.3390\/cells13151251","journal-title":"Cells"},{"issue":"5","key":"4278_CR44","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/08820538.2023.2168485","volume":"38","author":"L Yavuz Saricay","year":"2023","unstructured":"Yavuz Saricay L, Gonzalez Monroy JE, Fulton AB (2023) Can nerve growth factor (NGF) be a treatment option for pediatric eye diseases. Semin Ophthalmol 38(5):427\u2013432. https:\/\/doi.org\/10.1080\/08820538.2023.2168485","journal-title":"Semin Ophthalmol"},{"issue":"9","key":"4278_CR45","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1007\/s10787-025-01913-9","volume":"33","author":"Q Kong","year":"2025","unstructured":"Kong Q, Jiang Y, Li X, Lu X (2025) Regulation of toll-like receptor signaling pathways in age-related eye disease: from mechanisms to targeted therapeutics. Inflammopharmacology 33(9):5257\u20135271. https:\/\/doi.org\/10.1007\/s10787-025-01913-9","journal-title":"Inflammopharmacology"},{"key":"4278_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2023.109748","volume":"238","author":"D Song","year":"2024","unstructured":"Song D, Yang Q, Li X, Chen K, Tong J, Shen Y (2024) The role of the JAK\/STAT3 signaling pathway in acquired corneal diseases. Exp Eye Res 238:109748. https:\/\/doi.org\/10.1016\/j.exer.2023.109748","journal-title":"Exp Eye Res"},{"key":"4278_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100866","volume":"80","author":"Z Zhong","year":"2021","unstructured":"Zhong Z, Su G, Kijlstra A, Yang P (2021) Activation of the interleukin-23\/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res 80:100866. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100866","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"4278_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11302-022-09851-9","volume":"19","author":"JN Wang","year":"2023","unstructured":"Wang JN, Fan H, Song JT (2023) Targeting purinergic receptors to attenuate inflammation of dry eye. Purinergic Signal 19(1):199\u2013206. https:\/\/doi.org\/10.1007\/s11302-022-09851-9","journal-title":"Purinergic Signal"},{"key":"4278_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2023.109418","volume":"229","author":"J Shen","year":"2023","unstructured":"Shen J, Liang Y, Bi Z et al (2023) Cyclosporin A improves the hyperosmotic response in an experimental dry eye model by inhibiting the HMGB1\/TLR4\/NF-\u03baB signaling pathway. Exp Eye Res 229:109418. https:\/\/doi.org\/10.1016\/j.exer.2023.109418","journal-title":"Exp Eye Res"},{"key":"4278_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178104","volume":"1006","author":"J Gong","year":"2025","unstructured":"Gong J, Du T, Ding G et al (2025) Targeting the NLRP3 inflammasome: Pharmacological mec-hanisms for the treatment of dry eye disease. Eur J Pharmacol 1006:178104. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178104","journal-title":"Eur J Pharmacol"},{"key":"4278_CR51","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jtos.2024.09.007","volume":"34","author":"J Ge","year":"2024","unstructured":"Ge J, Li X, Xia Y et al (2024) Recent advances in NLRP3 inflammasome in corneal diseases: preclinical insights and therapeutic implications. Ocul Surf 34:392\u2013405. https:\/\/doi.org\/10.1016\/j.jtos.2024.09.007","journal-title":"Ocul Surf"},{"issue":"8","key":"4278_CR52","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/febs.17204","volume":"292","author":"M Zouali","year":"2025","unstructured":"Zouali M (2025) Swaying the advantage: multifaceted functions of inflammasomes in adaptive immunity. FEBS J 292(8):1817\u20131832. https:\/\/doi.org\/10.1111\/febs.17204","journal-title":"FEBS J"},{"key":"4278_CR53","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jtos.2025.01.005","volume":"36","author":"L Lian","year":"2025","unstructured":"Lian L, Ye X, Wang Z et al (2025) Hyperosmotic stress-induced NLRP3 inflammasome activation via the mechanosensitive PIEZO1 channel in dry eye corneal epithelium. Ocul Surf 36:106\u2013118. https:\/\/doi.org\/10.1016\/j.jtos.2025.01.005","journal-title":"Ocul Surf"},{"key":"4278_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OPTO.S350185","volume":"15","author":"DA Semp","year":"2023","unstructured":"Semp DA, Beeson D, Sheppard AL, Dutta D, Wolffsohn JS (2023) Artificial tears a systematic review. Clin Optom 15:9\u201327","journal-title":"Clin Optom"},{"issue":"5","key":"4278_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052434","volume":"23","author":"M Labetoulle","year":"2022","unstructured":"Labetoulle M, Benitez-Del-Castillo JM, Barabino S et al (2022) Artificial tears: biological role of their ingredients in the management of dry eye disease. Int J Mol Sci 23(5):2434. https:\/\/doi.org\/10.3390\/ijms23052434","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4278_CR56","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1080\/02713683.2022.2093381","volume":"47","author":"G Montani","year":"2022","unstructured":"Montani G, Landini L, Martino M (2022) Short- and long-term effects of a multi-component, artificial tear on preocular tear film stability, tear evaporation and tear film optical dynamic: a prospective randomized double-phase study. Curr Eye Res 47(9):1252\u20131258. https:\/\/doi.org\/10.1080\/02713683.2022.2093381","journal-title":"Curr Eye Res"},{"issue":"6","key":"4278_CR57","doi-asserted-by":"publisher","first-page":"e20250153","DOI":"10.5935\/0004-2749.2025-0153","volume":"88","author":"LCD Santos","year":"2025","unstructured":"Santos LCD, Affonso A, Belfort R, Freitas D (2025) Efficacy of povidone and propylene glycol-based artificial tears in the treatment of dry eye disease. Arq Bras Oftalmol 88(6):e20250153. https:\/\/doi.org\/10.5935\/0004-2749.2025-0153","journal-title":"Arq Bras Oftalmol"},{"issue":"1","key":"4278_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2020-000697","volume":"6","author":"M Kim","year":"2021","unstructured":"Kim M, Lee Y, Mehra D, Sabater AL, Galor A (2021) Dry eye: why artificial tears are not always the answer. BMJ Open Ophthalmol 6(1):e000697. https:\/\/doi.org\/10.1136\/bmjophth-2020-000697","journal-title":"BMJ Open Ophthalmol"},{"issue":"8","key":"4278_CR59","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.90714","volume":"17","author":"CY Lee","year":"2025","unstructured":"Lee CY, Chang CK, Chang YL, Yang SF, Huang CT (2025) Use of lipid-containing nanoemulsion artificial tears in patients with combined dry eye disease and meibomian gland dysfunction: a retrospective cohort study. Cureus 17(8):e90714. https:\/\/doi.org\/10.7759\/cureus.90714","journal-title":"Cureus"},{"key":"4278_CR60","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jtos.2024.08.006","volume":"34","author":"A Ranjan","year":"2024","unstructured":"Ranjan A, Basu S, Singh S (2024) Punctal cautery in dry eye disease: A systematic review. Ocul Surf 34:235\u2013240. https:\/\/doi.org\/10.1016\/j.jtos.2024.08.006","journal-title":"Ocul Surf"},{"issue":"6","key":"4278_CR61","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/01676830.2025.2500059","volume":"44","author":"F Zamorano-Mart\u00edn","year":"2025","unstructured":"Zamorano-Mart\u00edn F, Rebollo-Ram\u00edrez W, Ballesteros-S\u00e1nchez A et al (2025) Punctal occlusion versus artificial tears and lid hygiene in the management of dry anophthalmic socket syndrome: a randomized controlled trial. Orbit 44(6):729\u2013735. https:\/\/doi.org\/10.1080\/01676830.2025.2500059","journal-title":"Orbit"},{"issue":"6","key":"4278_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006775.pub3","volume":"6","author":"AM Ervin","year":"2017","unstructured":"Ervin AM, Law A, Pucker AD (2017) Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 6(6):CD006775. https:\/\/doi.org\/10.1002\/14651858.CD006775.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"4278_CR63","doi-asserted-by":"publisher","first-page":"1700163","DOI":"10.3389\/fopht.2025.1700163","volume":"5","author":"X Bian","year":"2025","unstructured":"Bian X, Ma J, Liu Y et al (2025) Cyclosporine a in the treatment of dry eye disease a narrative review. Front Ophthalmol (Lausanne) 5:1700163. https:\/\/doi.org\/10.3389\/fopht.2025.1700163","journal-title":"Front Ophthalmol (Lausanne)"},{"issue":"1","key":"4278_CR64","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/08820538.2025.2512759","volume":"41","author":"MB Doctor","year":"2026","unstructured":"Doctor MB, Kate A, Tallapelly HG, Basu S (2026) The role of topical cyclosporine A in ocular surface inflammatory disorders. Semin Ophthalmol 41(1):119\u2013130. https:\/\/doi.org\/10.1080\/08820538.2025.2512759","journal-title":"Semin Ophthalmol"},{"issue":"15","key":"4278_CR65","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.15.48","volume":"66","author":"X Han","year":"2025","unstructured":"Han X, Zhang J, Chen C et al (2025) Cyclosporine a ameliorates inflammatory responses in dry eye by inactivating cGAS-STING signaling via the initiation of autophagy. Invest Ophthalmol Vis Sci 66(15):48. https:\/\/doi.org\/10.1167\/iovs.66.15.48","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4278_CR66","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2147\/OPTH.S505641","volume":"19","author":"A Bari","year":"2025","unstructured":"Bari A, Dasgupta A, Agarwal T, Dada T, Sharma N (2025) Clinical efficacy and safety of preservative free cyclosporine in dry eye disease. Clin Ophthalmol 19:1149\u20131154. https:\/\/doi.org\/10.2147\/OPTH.S505641","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"4278_CR67","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-025-03104-9","volume":"26","author":"P Chaudhari","year":"2025","unstructured":"Chaudhari P, Ghate VM, Nampoothiri M, Lewis SA (2025) Cyclosporine a eluting nano drug reservoir film for the management of dry eye disease. AAPS PharmSciTech 26(5):109. https:\/\/doi.org\/10.1208\/s12249-025-03104-9","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"4278_CR68","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4155\/cli.14.135","volume":"5","author":"P Ames","year":"2015","unstructured":"Ames P, Galor A (2015) Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence. Clin Investig (Lond) 5(3):267\u2013285. https:\/\/doi.org\/10.4155\/cli.14.135","journal-title":"Clin Investig (Lond)"},{"key":"4278_CR69","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jtos.2022.08.010","volume":"26","author":"RR Vernhardsdottir","year":"2022","unstructured":"Vernhardsdottir RR, Magno MS, Hynnekleiv L et al (2022) Antibiotic treatment for dry eye disease related to meibomian gland dysfunction and blepharitis - a review. Ocul Surf 26:211\u2013221. https:\/\/doi.org\/10.1016\/j.jtos.2022.08.010","journal-title":"Ocul Surf"},{"key":"4278_CR70","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.2147\/OPTH.S480719","volume":"18","author":"ZM Bukhari","year":"2024","unstructured":"Bukhari ZM, Alsudais AS, Bshnaq AG et al (2024) Oral azithromycin versus oral doxycycline in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Clin Ophthalmol 18:3353\u20133363. https:\/\/doi.org\/10.2147\/OPTH.S480719","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"4278_CR71","doi-asserted-by":"publisher","first-page":"516","DOI":"10.4103\/tjo.TJO-D-25-00109","volume":"15","author":"R Arita","year":"2025","unstructured":"Arita R (2025) Targeted therapies for meibomian gland dysfunction - The role of antibiotics in meibomian gland dysfunction management. Taiwan J Ophthalmol. 15(4):516\u2013525. https:\/\/doi.org\/10.4103\/tjo.TJO-D-25-00109","journal-title":"Taiwan J Ophthalmol."},{"issue":"13","key":"4278_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30132863","volume":"30","author":"M Dzi\u0119gielewska","year":"2025","unstructured":"Dzi\u0119gielewska M, Tomczyk M, Wiater A, Woyto\u0144 A, Junka A (2025) Targeting ocular biofilms with plant-derived antimicrobials in the era of antibiotic resistance. Molecules 30(13):2863. https:\/\/doi.org\/10.3390\/molecules30132863","journal-title":"Molecules"},{"issue":"10","key":"4278_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015070.pub2","volume":"10","author":"SH Liu","year":"2022","unstructured":"Liu SH, Saldanha IJ, Abraham AG et al (2022) Topical corticosteroids for dry eye. Cochrane Database Syst Rev 10(10):CD015070. https:\/\/doi.org\/10.1002\/14651858.CD015070.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4278_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2025.110777","volume":"263","author":"Y Ma","year":"2026","unstructured":"Ma Y, Zhang Z, Jia Z et al (2026) Tacrolimus exerts anti-inflammatory effects in moderate to severe dry eye through activation of autophagy-lysosomal pathway. Exp Eye Res 263:110777. https:\/\/doi.org\/10.1016\/j.exer.2025.110777","journal-title":"Exp Eye Res"},{"issue":"11","key":"4278_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/life15111785","volume":"15","author":"M Zeppieri","year":"2025","unstructured":"Zeppieri M, Gagliano C, Avitabile A et al (2025) Platelets in dry eye disease: a narrative review of biological mechanisms and therapeutic applications derived from platelets. Life (Basel) 15(11):1785. https:\/\/doi.org\/10.3390\/life15111785","journal-title":"Life (Basel)"},{"key":"4278_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178387","volume":"1009","author":"L Chen","year":"2025","unstructured":"Chen L, Wei X, Zhang Z, Lu Y, Huang LS, Zhang H (2025) Rosarin alleviates dry eye disease via suppressing NF-\u03baB signal mediated inflammation and M1 polarization in macrophage. Eur J Pharmacol 1009:178387. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178387","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"4278_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70077","volume":"13","author":"Z Hu","year":"2025","unstructured":"Hu Z, Chen X, Hu Q, Zou M, Liu Z (2025) Role of Chinese medicine monomers in dry eye disease: breaking the vicious cycle of inflammation. Pharmacol Res Perspect 13(2):e70077. https:\/\/doi.org\/10.1002\/prp2.70077","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"4278_CR78","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/ame2.70000","volume":"8","author":"Z Liu","year":"2025","unstructured":"Liu Z, Li Y, Bao J et al (2025) Astaxanthin ameliorates benzalkonium chloride-induced dry eye disease through suppressing inflammation and oxidative stress via Keap1-Nrf2\/HO-1 signaling pathways. Anim Model Exp Med 8(6):1056\u20131079. https:\/\/doi.org\/10.1002\/ame2.70000","journal-title":"Anim Model Exp Med"},{"issue":"12","key":"4278_CR79","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.12.50","volume":"66","author":"S Zhang","year":"2025","unstructured":"Zhang S, Sha Y, Xie Y, Hong J (2025) Kaempferol alleviates dry eye disease via modulation of the IDH3B\/CCAR2\/IKBKB axis. Invest Ophthalmol Vis Sci 66(12):50. https:\/\/doi.org\/10.1167\/iovs.66.12.50","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"4278_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-04078-9","volume":"25","author":"A Habibi","year":"2025","unstructured":"Habibi A, Khosravi A, Soleimani M, Nejabat M, Dara M, Azarpira N (2025) Efficacy of topical mesenchymal stem cell exosome in Sj\u00f6gren\u2019s syndrome-related dry eye: a randomized cl-inical trial. BMC Ophthalmol 25(1):299. https:\/\/doi.org\/10.1186\/s12886-025-04078-9","journal-title":"BMC Ophthalmol"},{"issue":"11","key":"4278_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112264","volume":"18","author":"AJ Villatoro","year":"2017","unstructured":"Villatoro AJ, Fern\u00e1ndez V, Claros S et al (2017) Regenerative therapies in dry eye disease: from growth factors to cell therapy. Int J Mol Sci 18(11):2264. https:\/\/doi.org\/10.3390\/ijms18112264","journal-title":"Int J Mol Sci"},{"issue":"Suppl 277","key":"4278_CR82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/aos.15739","volume":"101","author":"M M\u00f8ller-Hansen","year":"2023","unstructured":"M\u00f8ller-Hansen M (2023) Mesenchymal stem cell therapy in aqueous deficient dry eye disease. Acta Ophthalmol 101(Suppl 277):3\u201327. https:\/\/doi.org\/10.1111\/aos.15739","journal-title":"Acta Ophthalmol"},{"issue":"15","key":"4278_CR83","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.15.22","volume":"66","author":"Y Lu","year":"2025","unstructured":"Lu Y, Wan X, Ye H et al (2025) Sphingomyelin synthase 2 deletion mitigates oxidative stress-induced NF-\u03baB activation via lipid metabolic reprogramming in dry eye disease. Invest Ophthalmol Vis Sci 66(15):22. https:\/\/doi.org\/10.1167\/iovs.66.15.22","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"22","key":"4278_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12227026","volume":"12","author":"WX Wang","year":"2023","unstructured":"Wang WX, Ko ML (2023) Efficacy of omega-3 intake in managing dry eye disease: a systematic review and meta-analysis of randomized controlled trials. J Clin Med 12(22):7026. https:\/\/doi.org\/10.3390\/jcm12227026","journal-title":"J Clin Med"},{"issue":"49","key":"4278_CR85","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000046566","volume":"104","author":"MS Almutairi","year":"2025","unstructured":"Almutairi MS, Almutleb ES, Bajsair AA et al (2025) Potential ocular health benefit of short-term omega-3 fatty acids supplementation on the ocular tear film: an observational study. Medicine (Baltimore) 104(49):e46566. https:\/\/doi.org\/10.1097\/MD.0000000000046566","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"4278_CR86","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.4103\/IJO.IJO_2789_22","volume":"71","author":"R Bhargava","year":"2023","unstructured":"Bhargava R, Pandey K, Ranjan S, Mehta B, Malik A (2023) Omega-3 fatty acids supplements for dry eye - are they effective or ineffective. Indian J Ophthalmol 71(4):1619\u20131625. https:\/\/doi.org\/10.4103\/IJO.IJO_2789_22","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"4278_CR87","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/ICO.0000000000001884","volume":"38","author":"G Giannaccare","year":"2019","unstructured":"Giannaccare G, Pellegrini M, Sebastiani S et al (2019) Efficacy of omega-3 fatty acid supplementation for treatment of dry eye disease: a meta-analysis of randomized clinical trials. Cornea 38(5):565\u2013573. https:\/\/doi.org\/10.1097\/ICO.0000000000001884","journal-title":"Cornea"},{"issue":"1","key":"4278_CR88","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/08820538.2025.2522716","volume":"41","author":"A Ferraro","year":"2026","unstructured":"Ferraro A, Laborante M, Cutrupi F, Salerno A, Coassin M, Di Zazzo A (2026) Immunological impact of sex hormones at ocular surface: a narrative review. Semin Ophthalmol 41(1):154\u2013163. https:\/\/doi.org\/10.1080\/08820538.2025.2522716","journal-title":"Semin Ophthalmol"},{"issue":"8","key":"4278_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083833","volume":"26","author":"S Ka\u0161telan","year":"2025","unstructured":"Ka\u0161telan S, Hat K, Tomi\u0107 Z, Mateji\u0107 T, Gotovac N (2025) Sex differences in the lacrimal gland: implications for dry eye disease. Int J Mol Sci 26(8):3833. https:\/\/doi.org\/10.3390\/ijms26083833","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4278_CR90","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.4103\/IJO.IJO_2887_22","volume":"71","author":"B Gorimanipalli","year":"2023","unstructured":"Gorimanipalli B, Khamar P, Sethu S, Shetty R (2023) Hormones and dry eye disease. Indian J Ophthalmol 71(4):1276\u20131284. https:\/\/doi.org\/10.4103\/IJO.IJO_2887_22","journal-title":"Indian J Ophthalmol"},{"key":"4278_CR91","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jtos.2025.06.002","volume":"38","author":"JR Jiang","year":"2025","unstructured":"Jiang JR, Khankan R, Ridder WH 3rd, Nguyen AL, Paugh JR (2025) A pilot randomized controlled trial of topical androgen treatment in dry eye. Ocul Surf 38:56\u201363. https:\/\/doi.org\/10.1016\/j.jtos.2025.06.002","journal-title":"Ocul Surf"},{"issue":"2","key":"4278_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021458","volume":"24","author":"M Rolando","year":"2023","unstructured":"Rolando M, Barabino S (2023) Dry eye disease: what is the role of vitamin D? Int J Mol Sci 24(2):1458. https:\/\/doi.org\/10.3390\/ijms24021458","journal-title":"Int J Mol Sci"},{"issue":"27","key":"4278_CR93","doi-asserted-by":"publisher","first-page":"19450","DOI":"10.1074\/jbc.M113.467670","volume":"288","author":"Y Chen","year":"2013","unstructured":"Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC (2013) Vitamin D receptor inhibits nuclear factor \u03baB activation by interacting with I\u03baB kinase \u03b2 protein. J Biol Chem 288(27):19450\u201319458. https:\/\/doi.org\/10.1074\/jbc.M113.467670","journal-title":"J Biol Chem"},{"issue":"5","key":"4278_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2024.102169","volume":"47","author":"Z Chen","year":"2024","unstructured":"Chen Z, Zhang C, Jiang J et al (2024) The efficacy of vitamin D supplementation in dry eye disease: a systematic review and meta-analysis. Contact Lens Anterior Eye 47(5):102169. https:\/\/doi.org\/10.1016\/j.clae.2024.102169","journal-title":"Contact Lens Anterior Eye"},{"issue":"4","key":"4278_CR95","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4103\/IJO.IJO_3020_22","volume":"71","author":"N Ashok","year":"2023","unstructured":"Ashok N, Khamar P, D\u2019Souza S et al (2023) Ion channels in dry eye disease. Indian J Ophthalmol 71(4):1215\u20131226. https:\/\/doi.org\/10.4103\/IJO.IJO_3020_22","journal-title":"Indian J Ophthalmol"},{"issue":"23","key":"4278_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/cells13232017","volume":"13","author":"CR Harrell","year":"2024","unstructured":"Harrell CR, Volarevic V (2024) Ion channels as potential drug targets in dry eye disease and their clinical relevance: a review. Cells 13(23):2017. https:\/\/doi.org\/10.3390\/cells13232017","journal-title":"Cells"},{"issue":"Pt 3","key":"4278_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117217","volume":"242","author":"D Qu","year":"2025","unstructured":"Qu D, Zhao L, Zhang Q, Li R, Li Y, Wang H (2025) Reprogramming the impact of glutamine metabolism on controlling the immunoinflammatory milieu in psoriasis. Biochem Pharmacol 242(Pt 3):117217. https:\/\/doi.org\/10.1016\/j.bcp.2025.117217","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4278_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02119-1","volume":"10","author":"X Chen","year":"2025","unstructured":"Chen X, Zhang C, Peng F et al (2025) Identification of glutamine as a potential therapeutic target in dry eye disease. Signal Transduct Target Ther 10(1):27. https:\/\/doi.org\/10.1038\/s41392-024-02119-1","journal-title":"Signal Transduct Target Ther"},{"key":"4278_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1709354","volume":"16","author":"Y Wei","year":"2025","unstructured":"Wei Y, Lin Y, Li Y et al (2025) Redefining cell death: ferroptosis as a gamechanger in ophth-almology. Front Immunol 16:1709354. https:\/\/doi.org\/10.3389\/fimmu.2025.1709354","journal-title":"Front Immunol"},{"issue":"10","key":"4278_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113527","volume":"28","author":"L Li","year":"2025","unstructured":"Li L, Chen B (2025) Ferroptosis and organelle roles in dry eye. iScience 28(10):113527. https:\/\/doi.org\/10.1016\/j.isci.2025.113527","journal-title":"iScience"},{"key":"4278_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2025.149853","volume":"974","author":"J Wang","year":"2026","unstructured":"Wang J, Zhang Z, Liu Y et al (2026) Identification of ferroptosis-related genes in dry eye disease and their effects on inflammatory response and immune infiltration. Gene 974:149853. https:\/\/doi.org\/10.1016\/j.gene.2025.149853","journal-title":"Gene"},{"issue":"4","key":"4278_CR102","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nelson JD, Azar DT et al (2017) TFOS DEWS II report executive summary. Ocul Surf 15(4):802\u2013812. https:\/\/doi.org\/10.1016\/j.jtos.2017.08.003","journal-title":"Ocul Surf"},{"issue":"21","key":"4278_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110699","volume":"26","author":"S Ka\u0161telan","year":"2025","unstructured":"Ka\u0161telan S, Kozina L, Tomi\u0107 Z, Bakija I, Mateji\u0107 T, Vidovi\u0107 D (2025) Dry eye disease and psychiatric disorders: neuroimmune mechanisms and therapeutic perspectives. Int J Mol Sci 26(21):10699. https:\/\/doi.org\/10.3390\/ijms262110699","journal-title":"Int J Mol Sci"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04278-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04278-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04278-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:49:15Z","timestamp":1790401755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04278-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4278"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04278-2","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No potential conflict of interest was reported by the author(s).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"408"}}